Beginning August 1, 2020, Premera Blue Cross is implementing updates for new and existing prior authorizations. The diabetes and asthma drugs in the table below will now require prior authorization.
| Condition | Drugs Requiring Prior Authorization |
| Diabetes | Steglatro (ertugliflozin) Invokana (canagliflozin) Segluromet (ertugliflozin-metformin) Invokamet (canagliflozin-metformin) Invokamet XR (canagliflozin-metformin) Onglyza (saxagliptin) Kombiglyze XR (saxagliptin-metformin) Basaglar (insulin glargine) |
| Asthma | Asmanex (mometasone furoate) Pulmicort (budesonide) Alvesco (ciclesonide) |
How Premera Blue Cross are notifying your clients
Employers will be notified of the prior authorization updates in next week’s Employer News communication.
Impacted members will receive a letter in the mail this month, June 2020, notifying them of the change. Preferred alternative drugs are available, and we are encouraging members to talk to their doctor to discuss their options and address any questions or concerns they may have.